Capmatinib

6 trials 2 recruiting LOncology

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

4 Completed trials

5 Sponsors

11 Countries

Phase III

Phase II

Phase I/II

Phase I (Other)

Phase III: 1 Phase II: 2 Phase I/II: 2 Phase I (Other): 1

Oversight events:

5 temporary halts 2 urgent safety measures across 2 trials

View oversight register →

Indications tested

Neoplasm malignant 1 Non-small cell lung cancer 1

Sponsors using this IMP

Novartis Pharma AG 2 Institut Gustave Roussy 1 Institut National De La Sante Et De La Recherche Medicale 1 Janssen - Cilag International 1 Oslo University Hospital HF 1

All trials

6 total

Improving public cancer care by implementing precision medicine in Norway Recruiting

2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Recruiting

2024-514791-40-00 Phase I/II 5 countries Institut Gustave Roussy
A Clinical Study to Evaluate the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small … Ended

2023-508256-19-00 Phase I/II 5 countries Janssen Cilag International
Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatme… Ended

2023-508841-42-00 Phase I (Other) 8 countries Novartis Pharma AG
Study to allow patients with cMET-dependent malignancies to continue capmatinib treatment Ended

2024-510948-31-00 Phase II 3 countries Novartis Pharma AG
MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study Ended

2024-514873-22-00 Phase III 1 country Institut National De La Sante Et De La Recherche Medicale

Showing 1–6 of 6 trials

← All drugs A–Z